Head-to-head · WeighScore
Hims & Hers vs June Health
The verdict
Hims & Hers takes it — 81/100 to 63/100.
Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Hims & Hers | June Health |
|---|---|---|
| WeighScore | 81/100 | 63/100 |
| Grade | B− | C |
| Scorecard rank | #36 | #261 |
| Semaglutide | $199/mo | $179/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $179/mo (starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #36 · B−
Strengths
- Nationwide
- Polished app
- Strong brand trust
Where it loses points
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Graded #261 · C
Strengths
- Offers both injectable and oral compounded semaglutide and tirzepatide
- Semaglutide starts at $179/mo (injectable) or $187/mo (tablets) — tirzepatide from $179/mo (injectable)
- Full per-dose price list published on-site with no signup required to view it
- Provider consult ('licensed clinician evaluation') is bundled into the displayed price
- Free discreet shipping advertised with 2-3 day delivery
Where it loses points
- No accessible Terms of Service or Privacy Policy — footer links go nowhere and standard URL guesses 404
- No LegitScript seal or other pharmacy-verification badge found anywhere on the site
- Legal entity, prescribing medical group, and compounding pharmacy partner are not named
- Domain was registered in May 2026 — a brand-new storefront with no independent reviews found
- Also sells 'MR-3' (retatrutide), a GLP-1/GIP/glucagon agonist with no FDA approval for any use
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.